$NOVN STILL REWARDS TO BE HAD 70% UPSIDE POTENTIAL.

************************A CAVALCADE OF GOOD NEWS LATELY IN NASDAQ:NOVN HAS SPURNED A EPIC RALLY FROM LATE APRIL. NOT TO WORRY IF YOU HAVE NOT BEEN INVOLVED THERE IS PLENTY OF ACTION LEFT IN THIS NAME AS INSIDERS HAVE BEEN BUYING UP SHARES. A BREAK ABOVE $2.45 IS A GOOD BUY SIGNAL ON GOOD VOLUME *********************

On May 6, it announced that it sold the economic rights to topical antiviral gel SB206 to Ligand Pharmaceuticals for up to $32M plus royalties. It plans to use the proceeds to advance the candidate through the registration process. If all goes well, commercial launch could happen in 2021.

AVERAGE ANALYSTS PRICE TARGET $6
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT

NOVAN INC.
Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide's natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. Its products pipeline include SB204, SB206, SB208, and SB414.